Periodontal Disease Treatment Market Size Study, by Disease Type, by Treatment Type, and Regional Forecasts 2022-2032

The global periodontal disease treatment market, valued at USD 2.44 billion in 2023, is poised for robust growth at a compound annual growth rate (CAGR) of 5.9% over the forecast period from 2024 to 2032. This expansion is primarily fueled by the rising prevalence of periodontal diseases, such as gingivitis and periodontitis, driven by poor oral hygiene, aging populations, and lifestyle factors like smoking. The increasing adoption of non-surgical treatments and advanced dental technologies further propels the market. Regulatory agencies such as the FDA, EMA, and MDR ensure the safety and efficacy of therapeutic products and dental devices, supporting market development.

Gingivitis dominates the market share among disease types due to its widespread occurrence. Factors like poor oral hygiene and systemic health conditions such as diabetes contribute to its prevalence, fostering a significant demand for preventive and therapeutic interventions. Non-surgical treatments, including scaling, root planning, and antimicrobial agents, are the preferred methods for managing early-stage periodontal diseases, offering cost-effectiveness and minimally invasive benefits.

Advancements in dental technologies, including laser-based therapies and biomaterials, have revolutionized periodontal treatments. Innovations like guided tissue regeneration and bone grafting provide effective solutions for severe periodontal diseases, addressing both functional restoration and aesthetic concerns.

Regional Insights

North America leads the market with a substantial revenue share, attributed to well-established healthcare infrastructure, high awareness levels, and favorable reimbursement policies. Europe follows closely, benefiting from stringent regulatory frameworks and ongoing investments in innovative dental therapies. The Asia Pacific region is set to witness the fastest growth, driven by increasing disposable incomes, heightened awareness about oral health, and government initiatives in countries like China, India, and Japan.

Competitive Landscape

Key players such as DENTSPLY SIRONA Inc., Straumann Group, and Henry Schein, Inc. are actively focusing on technological advancements, strategic partnerships, and expanding their product portfolios. These companies play a crucial role in enhancing the availability and accessibility of innovative periodontal disease treatments across global markets.

Major Companies Included in the Report:

• DENTSPLY SIRONA Inc.
• Straumann Group
• Henry Schein, Inc.
• BIOLASE, Inc.
• J. MORITA CORP.
• Geistlich Pharma AG
• Ultradent Products, Inc.
• Millennium Dental Technologies, Inc.
• BEGO GmbH & Co. KG
• AMD Lasers
• Brasseler USA
• DentalEZ, Inc.
• PreXion, Inc.
• Bien-Air Dental
• A-dec Inc.

Detailed Segments and Sub-segments:

By Disease Type:

• Gingivitis
• Acute Periodontitis
• Aggressive Periodontitis
• Others

By Treatment Type:

• Non-Surgical Treatment
  • Scaling and Root Planning
  • Antimicrobial Agents
  • Laser Therapy
• Flap Surgery
• Soft Tissue Graft
• Bone Grafting
• Guided Tissue Regeneration
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa

Years Considered for the Study:

• Historical Year: 2022
• Base Year: 2023
• Forecast Period: 2024-2032

Key Takeaways:

• Market estimates and 10-year forecasts highlight revenue trends across segments.
• Annualized revenue data offer insights into emerging regional and segment-specific opportunities.
• Comprehensive competitive landscape analysis focusing on major market players and their strategies.
• Analysis of industry challenges and opportunities, emphasizing technological advancements in non-invasive treatment solutions.